FindTrial
Sign In

SHR2554

DRUG10 trials

Sponsors

Jiangsu HengRui Medicine Co., Ltd., Fudan University, Ruijin Hospital, Henan Cancer Hospital, The First Affiliated Hospital of Zhengzhou University

Conditions

Advanced Breast CancerAdvanced Gastric CancerBreast CancerCastration-resistant Prostate CancerColorectal Cancer MetastaticFollicular LymphomaHealthy Adult SubjectsMalignant Tumor

Phase 1

A Phase 1 Study of SHR2554 in Subjects With Relapsed or Refractory Mature Lymphoid Neoplasms
Active, not recruitingNCT03603951
Jiangsu HengRui Medicine Co., Ltd.Relapsed or Refractory Mature Lymphoid Neoplasms
Start: 2018-08-14End: 2026-08-14Updated: 2024-10-01
A Study of SHR2554 Alone or in Combination With SHR3680 in the Treatment of mCRPC
TerminatedNCT03741712
Jiangsu HengRui Medicine Co., Ltd.Castration-resistant Prostate Cancer, Prostate Cancer
Start: 2018-11-20End: 2020-12-08Updated: 2021-02-05
A Food Effect Study of SHR2554 on Healthy Chinese Male Adult Subjects
CompletedNCT04335266
Jiangsu HengRui Medicine Co., Ltd.Healthy Adult Subjects
Start: 2019-08-06End: 2020-03-30Updated: 2020-04-06
A Umbrella Study in R/R PTCL Guided by Molecular Subtypes
RecruitingNCT05559008
Ruijin HospitalPeripheral T Cell Lymphoma
Start: 2022-09-30End: 2026-01-26Target: 116Updated: 2022-11-09
Pharmacokinetic Test of High-fat Diet After Oral Administration of SHR2554 in Healthy Subjects
CompletedNCT05592262
Jiangsu HengRui Medicine Co., Ltd.Malignant Tumor
Start: 2022-11-15End: 2022-12-14Updated: 2022-12-19

Phase 2

Molecularly Targeted Umbrella Study in Luminal Advanced Breast Cancer
NCT04355858
Fudan UniversityBreast Cancer, Metastatic Cancer
Start: 2020-05-01End: 2025-04-01Target: 319Updated: 2022-07-26
A Phase II Study of SHR2554 in Patients With Relapsed or Refractory Follicular Lymphoma
Not yet recruitingNCT06368167
Jiangsu HengRui Medicine Co., Ltd.Follicular Lymphoma
Start: 2024-04-30End: 2027-04-30Target: 105Updated: 2024-04-16
SHR-1701 Combined with SHR2554 and BP102 for MCRC
Not yet recruitingNCT06679673
Fudan UniversityColorectal Cancer Metastatic
Start: 2024-12-31End: 2026-12-31Target: 20Updated: 2024-11-07
SHR2554 Combined With Endocrine Therapy in Advanced Breast Cancer
Not yet recruitingNCT07125950
Henan Cancer HospitalAdvanced Breast Cancer
Start: 2025-09-30End: 2028-01-31Target: 60Updated: 2025-08-15
PD1/TGFβ In Combination With EZH2 And Chemotherapy For First - Line Treatment Of Gastric Cancer
RecruitingNCT07294664
The First Affiliated Hospital of Zhengzhou UniversityAdvanced Gastric Cancer, SHR1701
Start: 2025-06-15End: 2028-07-15Target: 36Updated: 2025-12-19

Related Papers

Abstract PO1-15-07: Subtyping-directed precision treatment refines traditional one-size-fits-all therapy in HR+/HER2- breast cancer: a sub-study of the MULAN umbrella trial
Cancer Research2024-05-02
ENHANCER OF ZESTE HOMOLOG 2 (EZH2) INHIBITOR SHR2554 IN RELAPSED OR REFRACTORY (<i>R/R</i>) PERIPHERAL T‐CELL LYMPHOMA (PTCL): UPDATED OUTCOMES FROM THE FIRST‐IN‐HUMAN PHASE 1 STUDY
Hematological Oncology2023-06-01
SHR2554, an EZH2 inhibitor, in relapsed or refractory mature lymphoid neoplasms: a first-in-human, dose-escalation, dose-expansion, and clinical expansion phase 1 trial.
2022-07-0135 citations
SHR2554, an enhancer of zeste homolog 2 (EZH2) inhibitor, in relapsed or refractory (r/r) mature lymphoid neoplasms: A first-in-human phase 1 study.
Journal of Clinical Oncology2022-06-011 citations